Additionally, the 36-month beta value for ALLO is 0.32. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 4 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for ALLO is 149.47M and currently, short sellers hold a 18.31% ratio of that float. The average trading volume of ALLO on June 11, 2025 was 3.33M shares.
ALLO) stock’s latest price update
The stock of Allogene Therapeutics Inc (NASDAQ: ALLO) has increased by 3.55 when compared to last closing price of 1.41.Despite this, the company has seen a gain of 8.15% in its stock price over the last five trading days. zacks.com reported 2025-06-04 that Allogene Therapeutics (ALLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ALLO’s Market Performance
Allogene Therapeutics Inc (ALLO) has experienced a 8.15% rise in stock performance for the past week, with a 25.86% rise in the past month, and a -28.08% drop in the past quarter. The volatility ratio for the week is 4.71%, and the volatility levels for the past 30 days are at 6.53% for ALLO. The simple moving average for the past 20 days is 22.42% for ALLO’s stock, with a -28.73% simple moving average for the past 200 days.
Analysts’ Opinion of ALLO
Citizens JMP, on the other hand, stated in their research note that they expect to see ALLO reach a price target of $5. The rating they have provided for ALLO stocks is “Mkt Outperform” according to the report published on March 14th, 2025.
Oppenheimer gave a rating of “Outperform” to ALLO, setting the target price at $11 in the report published on August 08th of the previous year.
ALLO Trading at 8.56% from the 50-Day Moving Average
After a stumble in the market that brought ALLO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.38% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALLO starting from MESSEMER DEBORAH M., who proposed sale 36,885 shares at the price of $1.42 back on Jun 10 ’25. After this action, MESSEMER DEBORAH M. now owns shares of Allogene Therapeutics Inc, valued at $52,391 using the latest closing price.
Yoshiyama Annie, the SVP, Finance of Allogene Therapeutics Inc, sale 9,601 shares at $1.41 during a trade that took place back on Apr 21 ’25, which means that Yoshiyama Annie is holding 130,663 shares at $13,537 based on the most recent closing price.
Stock Fundamentals for ALLO
Current profitability levels for the company are sitting at:
- 12222.09 for the present operating margin
- 1.0 for the gross margin
The net margin for Allogene Therapeutics Inc stands at 11469.23. The total capital return value is set at -0.56. Equity return is now at value -59.60, with -46.11 for asset returns.
Based on Allogene Therapeutics Inc (ALLO), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at -2.43. The debt to equity ratio resting at 0.21. The interest coverage ratio of the stock is -812.34.
Currently, EBITDA for the company is -243.33 million with net debt to EBITDA at -0.16. When we switch over and look at the enterprise to sales, we see a ratio of -16281.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.71.
Conclusion
In conclusion, Allogene Therapeutics Inc (ALLO) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
